Table 3 Risk of thromboembolic events of atrial fibrillation patients based on CHA₂DS₂-VASc score and oral anticoagulants (OACs)

Any OACs cohort

CHA₂DS₂-VASc of 0–1

- OACs

0.16 (0.01–0.90)

0.13 (0.01–1.49)

0.100

- No OACs

1.03 (0.41–2.12)

Reference

CHA₂DS₂-VASc of 2 or more

- OACs

1.52 (1.19–1.91)

0.74 (0.41–1.34)

0.740

- No OACs

2.34 (1.55–3.42)

Reference

Warfarin cohort

CHA₂DS₂-VASc of 0–1

- Warfarin

0.19 (0.01–1.07)

0.13 (0.01–1.57)

0.108

- No OACs

1.03 (0.41–2.12)

Reference

CHA₂DS₂-VASc of 2 or more

- Warfarin

1.58 (1.23-2.00)

0.77 (0.43–1.40)

0.391

- No OACs

2.34 (1.55–3.42)

Reference

DOACs cohort

CHA₂DS₂-VASc of 0–1

- DOACs

-

-

-

- No OACs

1.03 (0.41–2.12)

Reference

CHA₂DS₂-VASc of 2 or more

- DOACs

0.8 (0.17–2.37)

0.56 (0.13–2.48)

0.444

- No OACs

2.34 (1.55–3.42)

Reference